Comparative clinical study to evaluate and compare clinical and microbiological efficacies between cefotaxime and cefuroxime, when administered intravenously to women with acute pyelonephritis

Randomized, single blind, controlled, multicenter, comparative clinical study to evaluate and compare clinical and microbiological efficacies between cefotaxime and cefuroxime, when administered intravenously to women with community-acquired acute pyelonephritis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0000658

Enrollment

832

Registered

2013-02-04

Start date

2011-02-25

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Cefuroxime group: cefuroxime 750 mg, three times per day, intravenously Cefotaxime group: cefotaxime 2g, three times per day, intravenously

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: women with community-acquired acute pyelonephritis age: above 19 years old

Exclusion criteria

Exclusion criteria: hospital-acquired infection Pregnancy

Design outcomes

Primary

Measure	Time frame
Clinical, microbiological efficacies	—

Secondary

Measure	Time frame
Time to defervescence	—

Countries

Korea, Republic of

Contacts

Public ContactKyung-Ah Cha

The Catholic University of Korea, St. Vincent's Hospital

Outcome results